JP2018529762A5 - - Google Patents

Download PDF

Info

Publication number
JP2018529762A5
JP2018529762A5 JP2018530676A JP2018530676A JP2018529762A5 JP 2018529762 A5 JP2018529762 A5 JP 2018529762A5 JP 2018530676 A JP2018530676 A JP 2018530676A JP 2018530676 A JP2018530676 A JP 2018530676A JP 2018529762 A5 JP2018529762 A5 JP 2018529762A5
Authority
JP
Japan
Prior art keywords
weight percent
present
pharmaceutically acceptable
niclosamide
colitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018530676A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529762A (ja
JP6955648B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/050012 external-priority patent/WO2017040864A1/en
Publication of JP2018529762A publication Critical patent/JP2018529762A/ja
Publication of JP2018529762A5 publication Critical patent/JP2018529762A5/ja
Priority to JP2021036866A priority Critical patent/JP7189983B2/ja
Application granted granted Critical
Publication of JP6955648B2 publication Critical patent/JP6955648B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018530676A 2015-09-01 2016-09-01 異常炎症反応に関連する状態を処置するための方法および組成物 Expired - Fee Related JP6955648B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021036866A JP7189983B2 (ja) 2015-09-01 2021-03-09 異常炎症反応に関連する状態を処置するための方法および組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562213016P 2015-09-01 2015-09-01
US62/213,016 2015-09-01
US201562241508P 2015-10-14 2015-10-14
US62/241,508 2015-10-14
PCT/US2016/050012 WO2017040864A1 (en) 2015-09-01 2016-09-01 Methods and compositions for treating conditions associated with an abnormal inflammatory responses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021036866A Division JP7189983B2 (ja) 2015-09-01 2021-03-09 異常炎症反応に関連する状態を処置するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2018529762A JP2018529762A (ja) 2018-10-11
JP2018529762A5 true JP2018529762A5 (enExample) 2019-10-10
JP6955648B2 JP6955648B2 (ja) 2021-10-27

Family

ID=58097295

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018530676A Expired - Fee Related JP6955648B2 (ja) 2015-09-01 2016-09-01 異常炎症反応に関連する状態を処置するための方法および組成物
JP2021036866A Active JP7189983B2 (ja) 2015-09-01 2021-03-09 異常炎症反応に関連する状態を処置するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021036866A Active JP7189983B2 (ja) 2015-09-01 2021-03-09 異常炎症反応に関連する状態を処置するための方法および組成物

Country Status (21)

Country Link
US (11) US10292951B2 (enExample)
EP (1) EP3344274A4 (enExample)
JP (2) JP6955648B2 (enExample)
KR (1) KR20180080189A (enExample)
CN (1) CN109562137A (enExample)
AU (2) AU2016315852B2 (enExample)
BR (1) BR112018004069A2 (enExample)
CA (1) CA2997136A1 (enExample)
CL (1) CL2021000622A1 (enExample)
CO (1) CO2018003465A2 (enExample)
CR (1) CR20180185A (enExample)
EA (1) EA201890618A1 (enExample)
HK (1) HK1258048A1 (enExample)
IL (1) IL257801A (enExample)
MX (3) MX2018002586A (enExample)
PE (1) PE20181295A1 (enExample)
PH (1) PH12018500448A1 (enExample)
SG (1) SG10201914118SA (enExample)
TN (1) TN2018000069A1 (enExample)
UA (1) UA125747C2 (enExample)
WO (1) WO2017040864A1 (enExample)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122150A1 (en) 2005-05-10 2006-11-16 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
KR101847107B1 (ko) 2008-07-08 2018-04-10 인사이트 홀딩스 코포레이션 인돌아민 2,3-디옥시게나아제의 억제제로서의 1,2,5-옥사디아졸
PL3061821T3 (pl) 2009-07-22 2020-01-31 PureTech Health LLC Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CA2960331A1 (en) 2014-09-12 2016-03-17 Antibiotx Aps Antibacterial use of halogenated salicylanilides
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
CN104880428B (zh) * 2015-06-23 2016-07-06 山西振东安特生物制药有限公司 一种胶体果胶铋或含胶体果胶铋制剂中铋含量的测定方法
UA125747C2 (uk) 2015-09-01 2022-06-01 Фьост Вейв Байо, Інк. Способи та композиції для лікування станів, пов'язаних із аномальною запальною відповіддю
CA3004083A1 (en) * 2015-11-04 2017-05-11 Incyte Corporation Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
WO2018170254A1 (en) 2017-03-15 2018-09-20 Georgetown University Treating cancer with a cck receptor inhibitor and an immune checkpoint inhibitor
JP7298928B2 (ja) 2017-03-21 2023-06-27 ノヴァリード ファーマ インク ホスホジエステラーゼの阻害及びその関連障害のための治療剤
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
BR112019022873A8 (pt) 2017-05-02 2023-04-11 Merck Sharp & Dohme Formulação, e, vaso ou dispositivo de injeção.
KR102459936B1 (ko) * 2017-10-13 2022-10-27 주식회사 엘지생활건강 알칸닌을 포함하는 구강질환 예방 또는 치료용 조성물
WO2019126739A1 (en) 2017-12-21 2019-06-27 Shepherd Therapeutics, Inc. Pyrvinium pamoate anti-cancer therapies
WO2019191032A1 (en) 2018-03-26 2019-10-03 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
EP3818010A4 (en) 2018-07-03 2022-08-17 Fennec Pharmaceuticals, Inc. Anhydrous sodium thiosulfate and formulations thereof
IL261670B (en) * 2018-09-06 2019-06-30 Tudu Holdings Ltd A preparation that includes magnesium and its uses
CN109180600A (zh) * 2018-09-21 2019-01-11 五邑大学 一种麝香草酚类似物及其应用
CN112789042A (zh) 2018-09-28 2021-05-11 卡鲁娜治疗学有限公司 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3639822A1 (en) * 2018-10-15 2020-04-22 Universität Regensburg Compound for use in the treatment of a disease characterized by dysregulated mucus production and/or secretion
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
EP3873941A4 (en) * 2018-10-31 2022-07-27 Merck Sharp & Dohme Corp. ANTI-HUMAN PD-1 ANTIBODY CRYSTALS AND METHODS OF USE THEREOF
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
WO2020198051A1 (en) * 2019-03-22 2020-10-01 Mannkind Corporation Inhalable dry powders
MA55726A (fr) * 2019-04-18 2022-02-23 Prevep Llc Associations thérapeutiques, compositions pharmaceutiques liquides, kits pour leur préparation et leurs méthodes d'utilisation
WO2020220170A1 (zh) * 2019-04-28 2020-11-05 深圳市中医院 氯硝柳胺乙醇胺盐在制备治疗系统性红斑狼疮及其并发症的药物中的应用
CN112007036B (zh) * 2019-05-29 2022-01-21 百岳特生物科技(上海)有限公司 化合物及其组合物用于制备缓解肺上皮细胞发炎的医药品的用途
CN110200935B (zh) * 2019-06-03 2021-03-02 浙江得恩德制药股份有限公司 一种胶体果胶铋胶囊及其制备工艺
EP3998063A4 (en) * 2019-07-08 2023-03-15 MORESCO Corporation Compositions for preparing microemulsion, microemulsion, method for producing composition and microemulsion, and use of microemulsion
CN112341397B (zh) * 2019-08-09 2023-05-23 成都苑东生物制药股份有限公司 吡嗪类衍生物或盐、异构体、其制备方法及用途
EP3797771B1 (en) * 2019-09-03 2022-02-23 Square Power Ltd Rebamipide for use in prophylaxis and treatment of celiac disease
US20210114973A1 (en) * 2019-10-18 2021-04-22 First Wave Bio, Inc. Pharmaceutical formulations
KR102300846B1 (ko) * 2019-11-01 2021-09-09 서울대학교산학협력단 면역 활성 개선용 조성물 및 이의 방법
CN111122523B (zh) * 2019-12-06 2021-09-28 山西大学 一种快速识别Ag+和Cys的三相输出功能的分子逻辑门及其构建方法
WO2021142240A1 (en) 2020-01-10 2021-07-15 First Wave Bio, Inc. Compositions comprising niclosamide for use in treating conditions associated with an abnormal inflammatory response
WO2021142238A1 (en) 2020-01-10 2021-07-15 First Wave Bio, Inc. Deuterated niclosamide
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
US20230190684A1 (en) 2020-03-16 2023-06-22 First Wave Bio, Inc. Methods of treating covid-19 with a niclosamide compound
MA71423A (fr) * 2020-03-19 2025-04-30 Trizell Ltd. Système de stockage de virus sensible à la température
WO2021189018A1 (en) * 2020-03-20 2021-09-23 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
CN112914547A (zh) * 2020-03-22 2021-06-08 复旦大学附属华山医院 内源性神经干细胞磁共振无创性示踪技术体系及建立方法
IL296909A (en) * 2020-04-01 2022-12-01 Union Therapeutics As Formulation
US11045434B1 (en) 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease
WO2021226256A1 (en) * 2020-05-05 2021-11-11 Neurobo Pharmaceuticals, Inc. Niclosamide formulations and methods of use
AU2021270856A1 (en) * 2020-05-13 2022-12-08 The Regents Of The University Of California Thiol-containing compounds for use in treating coronavirus
CN112057623A (zh) * 2020-06-03 2020-12-11 江苏靶标生物医药研究所有限公司 一种磷脂酰丝氨酸在制备治疗炎症性肠病药物中的应用
WO2021255218A1 (en) * 2020-06-19 2021-12-23 Charité - Universitätsmedizin Berlin A pharmaceutical combination comprising an anti-viral protonophore and a serine protease inhibitor
CN111650307A (zh) * 2020-07-13 2020-09-11 重庆医药高等专科学校 一种同时对酒中解热镇痛类药品非法添加物定性定量检测的方法及应用
WO2022020659A1 (en) * 2020-07-23 2022-01-27 Purdue Research Foundation Ohpp-formulated niclosamide to treat sars-cov-2, other viral diseases, and cancers
CA3191727A1 (en) * 2020-08-14 2022-02-17 Mayo Foundation For Medical Education And Research Methods and materials for tissue ablation
WO2022046668A1 (en) * 2020-08-22 2022-03-03 Luc Montagnier Compositions and methods for reducing the transmissivity of illnesses
CN111920824A (zh) * 2020-09-11 2020-11-13 余朝权 一种治疗伤口的中药组合物
KR102636847B1 (ko) 2020-09-18 2024-02-19 경북대학교 산학협력단 티아민 유도체를 포함하는 이식편대숙주질환 예방 또는 치료용 약학적 조성물
CN114246852B (zh) * 2020-09-21 2024-08-16 暨南大学 一种药物组合物在心脑血管疾病中的应用
KR102378590B1 (ko) * 2020-09-28 2022-03-24 (주)위바이오트리 난용성 약물을 포함하는 금속 (수)산화물 복합체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
WO2022093871A1 (en) * 2020-10-26 2022-05-05 The Regents Of The University Of California Sars-c0v-2 inactivation by ethacridine
CN112342028B (zh) * 2020-10-28 2021-07-09 中铁建华南建设(广州)高科技产业有限公司 盾构分散剂及其制备方法和应用
WO2022091065A1 (ko) * 2020-11-02 2022-05-05 (주)아이엠디팜 신규한 공결정, 이를 포함하는 약학 조성물 및 이의 제조 방법
CN112526032B (zh) * 2020-12-28 2022-05-17 北京金城泰尔制药有限公司 聚甲酚磺醛的检测方法
WO2022147499A1 (en) * 2021-01-04 2022-07-07 Neurobo Pharmaceuticals, Inc. Method of treating viral infections with a combination of niclosamide and gemcabene
CN117062527A (zh) 2021-01-19 2023-11-14 埃里莫斯制药有限责任公司 作为冠状病毒抗病毒剂的Terameprocol和去甲二氢愈创木酸(NDGA)衍生物
CN116917267B (zh) * 2021-01-28 2025-08-12 Imd制药公司 包含卡莫司他及氯硝柳胺的共晶、包含其的药物组合物及其制备方法
CN112826795B (zh) * 2021-03-23 2022-08-30 重庆医科大学 一种载汉防己甲素脂质体制剂及其制备方法和应用
US20220304959A1 (en) * 2021-03-26 2022-09-29 First Wave Biopharma Treatment of long haulers syndrome with niclosamide
CN113368064B (zh) * 2021-06-08 2022-06-28 吉林津升制药有限公司 一种烟酸冻干粉及其制备方法
CN114134195B (zh) * 2021-11-03 2024-06-11 南方科技大学 预防前列腺癌的药剂的筛选方法、硝唑尼特在制药中的应用
US20230203604A1 (en) * 2021-11-23 2023-06-29 nference, inc. Detection of covid-19 associated cardiac injury and vaccine-associated myocarditis
CN113908154A (zh) * 2021-11-29 2022-01-11 中国药科大学 硝唑尼特及其体内代谢物替唑尼特在抗银屑病及银屑病样皮肤炎症中的应用
CN114393662A (zh) * 2021-12-21 2022-04-26 凭祥青山中密度纤维板有限公司 一种环保中密度纤维板的制备方法
JP2025518339A (ja) * 2022-01-31 2025-06-12 リビオネックス・インコーポレイテッド 鉄キレート化のための新規液体製剤
EP4486448A1 (en) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
CN114796135B (zh) * 2022-03-29 2023-04-07 海南久常制药有限公司 一种硫糖铝口服制剂及其制备方法
CN114652734A (zh) * 2022-03-31 2022-06-24 李红梦 一种祛痘的药物组合物及其制备方法
CN114767871B (zh) * 2022-04-19 2023-04-07 中国工程物理研究院机械制造工艺研究所 介孔硅载药体系及制备方法和介孔硅载药
WO2023217239A1 (zh) * 2022-05-12 2023-11-16 广州嘉越医药科技有限公司 一种药物组合及其应用
WO2024029639A1 (ko) * 2022-08-02 2024-02-08 제이투에이치바이오텍 주식회사 3성분 프로드럭, 이의 약학적 조성물 및 의약 용도
CN115494231A (zh) * 2022-09-02 2022-12-20 武汉三鹰生物技术有限公司 一种蛋白酶抑制剂混合物及其制备方法与应用
CN115739028B (zh) * 2022-11-26 2024-04-02 西南政法大学 一种精神活性物质吸附剂及其应用
CN116036289B (zh) * 2023-02-03 2025-05-06 中国药科大学 一种增强铁死亡治疗效果的纳米制剂及其制备方法和应用
CN116077424B (zh) * 2023-02-17 2025-06-03 重庆大学 一种多功能仿生水凝胶及其制备方法和应用
WO2024182078A1 (en) * 2023-02-28 2024-09-06 Verté Therapeutics, Llc Veterinary transdermal gel comprising ondansetron, and related methods
CN116139116A (zh) * 2023-03-30 2023-05-23 中南大学湘雅医院 氯硝柳胺在抑制急性肝衰竭中的应用
CN116531366B (zh) * 2023-05-23 2025-02-14 新乡医学院 罗替戈汀的药物新用途
WO2025037323A1 (en) * 2023-08-12 2025-02-20 Pavan Kumar Kothapuvari Pharmaceutical compositions for treatment of dry eye disease and associated disorders
CN117883443A (zh) * 2023-12-12 2024-04-16 中国海洋大学 吡罗克酮乙醇胺盐在制备治疗胃肠道疾病的药物中的应用
CN117899225A (zh) * 2024-01-19 2024-04-19 芮城绿曼生物药业有限公司 一种增强免疫力的兽用抗菌注射剂、制备方法及应用
WO2025216845A1 (en) * 2024-04-12 2025-10-16 Advancion Corporation Paint and coating formulations including 3-amino-2-butanol and uses thereof
CN119055625B (zh) * 2024-07-23 2025-09-09 湖北工业大学 Tiratricol在制备抗ADV7病毒药物中的应用
CN120204184A (zh) * 2025-02-17 2025-06-27 深圳市第三人民医院(深圳市肝病研究所) 阿米替林和/或其衍生物的应用、结核分枝杆菌抑制剂和药物组合物
CN119700664B (zh) * 2025-02-28 2025-06-20 山东新时代药业有限公司 含有活性成分琥珀酸普芦卡必利的注射液及其制备方法
CN120713881B (zh) * 2025-08-21 2025-12-05 南方科技大学 氯硝柳胺在治疗器官移植排斥反应中的应用

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3079297A (en) 1960-05-31 1963-02-26 Bayer Ag Method of combating gastropods
US3927195A (en) * 1974-01-31 1975-12-16 Lilly Industries Ltd Production of capsules
FR2505798B1 (fr) 1981-05-14 1986-07-25 Pari Symac Perfectionnement aux dispositifs comportant un ressort helicoidal utilise comme organe de transfert, d'extraction, de dosage ou de melange
NZ223200A (en) 1988-01-15 1989-01-06 Ancare Distributors Anthelmintic compositions containing 2',5-dicloro-4'-nitrosalicylanilide and non aqueous carrier
DE4005528C2 (de) 1990-02-22 1998-01-15 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
US5280784A (en) 1990-09-19 1994-01-25 Paul Ritzau Pari-Werk Gmbh Device in particular and inhalating device for treating the lung and the respiratory tracts
EP0504459B1 (de) 1991-03-21 1996-06-05 PAUL RITZAU PARI-WERK GmbH Vernebler insbesondere zur Anwendung in Geräten für die Inhalationstherapie
DK0540774T3 (da) 1991-11-07 1995-07-10 Ritzau Pari Werk Gmbh Paul Væskeforstøver
DK0540775T3 (da) 1991-11-07 1997-08-25 Ritzau Pari Werk Gmbh Paul Forstøver især til anvendelse i apparater til inhalationsterapi
DE4225928A1 (de) 1992-08-05 1994-02-10 Ritzau Pari Werk Gmbh Paul Zerstäubervorrichtung mit Heizeinrichtung
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
DE4310575C1 (de) 1993-03-31 1994-09-15 Ritzau Pari Werk Gmbh Paul Vorrichtung zum Erzeugen von Aerosolpulsen
EP0663241B1 (de) 1993-12-17 1998-07-15 PARI GmbH Spezialisten für effektive Inhalation Zerstäuberdüse
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US6000394A (en) 1994-10-26 1999-12-14 Paul Rizau Pari-Werk Gmbh Generation of an aerosol of an exact dose
US5663155A (en) * 1994-11-30 1997-09-02 The University Hospital Compositions for the treatment of parasitic infections
DE19520622C2 (de) 1995-06-06 2003-05-15 Pari Gmbh Vorrichtung zum Vernebeln von Fluiden
DE19602628C2 (de) 1996-01-25 2000-06-29 Pari Gmbh Vernebler
EP0821970A1 (en) 1996-08-02 1998-02-04 Edward Henri Charles Verhaeren Carrier composition for influencing the tight junction permeability
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
DE19734022C2 (de) 1997-08-06 2000-06-21 Pari Gmbh Inhalationstherapiegerät mit einem Ventil zur Begrenzung des Inspirationsflusses
US5905090A (en) 1998-04-29 1999-05-18 Italfarmaco S.P.A. Analogues of the active metabolite of leflunomide
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
DE19827228C2 (de) 1998-06-18 2000-07-13 Pari Gmbh Flüssigkeitszerstäubervorrichtung
EP1098641B1 (en) 1998-07-27 2016-04-27 St. Jude Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
DE19962110C2 (de) 1999-12-22 2003-06-12 Pari Gmbh Inhalationsvernebler mit einstückigem Ventilelement
AU2001260083A1 (en) * 2000-05-26 2001-12-03 Dr. Reddy's Research Foundation New pharmaceutical composition and the process for its preparation
WO2002049632A1 (en) 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibitors against the production and release of inflammatory cytokines
KR20030064852A (ko) 2000-12-22 2003-08-02 이시하라 산교 가부시끼가이샤 아닐린 유도체 또는 그의 염 및 이들을 함유하는사이토카인 생산 억제제
US20040022861A1 (en) 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
EP1357900A2 (en) 2001-01-30 2003-11-05 Board of Regents, The University of Texas System Process for production of nanoparticles and microparticles by spray freezing into liquid
US20040071757A1 (en) 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
AU2003249244A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
JP4933732B2 (ja) 2003-01-15 2012-05-16 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 低温表面上で凍結させることによって得られる薬物粒子
US7544712B1 (en) 2003-05-28 2009-06-09 National Health Research Insitutes Treatment of coronavirus infection
US20050123571A1 (en) 2003-06-06 2005-06-09 Rossini Aldo A. Modulation of apoptosis
US7249224B2 (en) 2003-08-05 2007-07-24 Newisys, Inc. Methods and apparatus for providing early responses from a remote data cache
DE10340277B4 (de) 2003-08-29 2006-11-23 Bio-Gate Bioinnovative Materials Gmbh Körperpflegemittel mit Silber-Agglomeraten
EP1774028A4 (en) 2004-07-07 2008-05-07 Dana Farber Cancer Inst Inc METHOD AND COMPOSITIONS FOR TREATING OBESITY
CN1626506A (zh) 2004-08-10 2005-06-15 李志良 高纯度、高收率氯硝柳胺的制备
WO2006026502A1 (en) 2004-08-27 2006-03-09 The Dow Chemical Company Enhanced delivery of drug compositions to treat life threatening infections
WO2006120178A1 (en) 2005-05-11 2006-11-16 Novo Nordisk A/S New haloalkylsulfone substituted compounds useful for treating obesity and diabetes
WO2006125781A2 (en) 2005-05-23 2006-11-30 Novo Nordisk A/S Haloalkoxy-substituted salicylic anilides
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
CA2659655A1 (en) 2006-08-08 2008-02-21 Alan M. Fogelman Salicylanilides enhance oral delivery of therapeutic peptides
US9044391B2 (en) 2007-01-10 2015-06-02 Board Of Regents, The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
ES2717154T3 (es) 2007-06-22 2019-06-19 Univ Texas Formación de partículas de péptido o proteína submicrométricas estables mediante congelación de película fina
US8262657B2 (en) 2007-08-16 2012-09-11 Nutek Orthopaedics, Inc. External fixation apparatus with adjustable pin clamping means and convergent bone pins
CA2711473C (en) 2008-01-10 2016-01-26 Evonik Roehm Gmbh Coated pharmaceutical or nutraceutical preparation with enhanced active substance release in the colon
EP2252275B1 (en) 2008-02-13 2017-11-29 Board of Regents, The University of Texas System Templated open flocs of anisotropic particles for enhanced pulmonary delivery
EP2123626A1 (en) 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
EP2348868A4 (en) 2008-10-22 2013-06-12 Metaproteomics Llc NEW MITOCHONDRIAL DECOMPOSITION PROCESSES AND COMPOSITIONS FOR IMPROVED THERMOGENESIS IN FAT CELLS
CU23701A1 (es) 2008-12-29 2011-09-21 Ct Ingenieria Genetica Biotech Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i
EA030679B1 (ru) 2009-06-26 2018-09-28 РОМАРК ЛЭБОРЕТЕРИЗ Эл.Си. Соединения и способы лечения гриппа
CN101601670B (zh) 2009-06-30 2014-06-04 青岛蔚蓝生物股份有限公司 一种宠物用复方氯硝柳胺驱虫片剂及其制备方法
KR100990110B1 (ko) 2009-08-18 2010-10-29 엘지전자 주식회사 태양 전지
WO2011035321A1 (en) 2009-09-21 2011-03-24 Duke University Treatment of wnt/frizzled-related diseases
US9206394B2 (en) * 2010-02-03 2015-12-08 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
GB201015079D0 (en) 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
JP5770304B2 (ja) 2010-11-16 2015-08-26 ユニバーシティ・オブ・メディシン・アンド・デンティストリー・オブ・ニュージャージーUniversity Of Medicine Anddentistry Of New Jersey 安全な化学的ミトコンドリア脱共役剤を用いたii型糖尿病及び糖尿病関連疾患の治療
WO2012143377A1 (en) 2011-04-18 2012-10-26 Max-Delbrück-Centrum für Molekulare Medizin Niclosamide for the treatment of cancer metastasis
WO2012154944A2 (en) 2011-05-10 2012-11-15 Stc.Unm Methods of treating autophagy-associated disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits
CA2841358A1 (en) * 2011-07-15 2013-01-24 S.L.A. Pharma Ag Pharmaceutical compositions for rectal administration
WO2013169939A2 (en) 2012-05-08 2013-11-14 Aeromics, Llc New methods
WO2014023329A1 (en) 2012-08-06 2014-02-13 Life And Brain Gmbh Niclosamide and its derivatives for use in the treatment of solid tumors
CN102861014A (zh) * 2012-10-16 2013-01-09 天津必佳药业集团有限公司 一种畜禽用抗蠕虫病复方氯硝柳胺片及其制备方法
CN103891720B (zh) * 2012-12-27 2016-02-17 陕西汤普森生物科技有限公司 一种含有螺枯威的复配杀螺组合物
CA2898113C (en) 2013-01-14 2022-05-31 Health Clinics Limited Combination cancer therapeutics and uses thereof
CA2902971A1 (en) * 2013-03-12 2014-09-18 Patheon, Inc. Drug delivery system
WO2014175852A1 (en) 2013-04-23 2014-10-30 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US9669036B2 (en) 2013-05-14 2017-06-06 The University Of Chicago Modulation of reactivation of a latent virus
WO2014200705A1 (en) * 2013-06-14 2014-12-18 Stc.Unm Treatment of autophagy-related disorders
US9951118B2 (en) * 2013-08-02 2018-04-24 The Regents Of The University Of California Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors
CN105899223A (zh) * 2013-10-28 2016-08-24 加利福尼亚大学董事会 转移性前列腺癌的治疗
JP7066321B2 (ja) 2014-01-10 2022-05-13 アヴァリン ファーマ インク. エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
CN103751854B (zh) 2014-01-20 2015-08-26 瞿介明 抗菌医用导管
TWI664289B (zh) 2014-10-23 2019-07-01 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
AR102537A1 (es) 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
JP6047203B2 (ja) 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および/または治療のための宿主防御タンパク質(hdp)模倣薬
US9566399B1 (en) 2015-04-14 2017-02-14 Clempharma LLC Deep lung alveolar aerosol targeted drug delivery
US20180147161A1 (en) 2015-05-01 2018-05-31 Board Of Regents, The University Of Texas System Multidrug brittle matrix compositions
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
CN105063018A (zh) * 2015-08-31 2015-11-18 山西大学 一种从葡萄成熟果实中提取总rna的方法
UA125747C2 (uk) 2015-09-01 2022-06-01 Фьост Вейв Байо, Інк. Способи та композиції для лікування станів, пов'язаних із аномальною запальною відповіддю
EP3168211A1 (en) 2015-11-10 2017-05-17 Westfälische Wilhelms-Universität Münster Pharmaceutical co-crystals of niclosamide
US10189797B2 (en) 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use
US10588864B2 (en) 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery
WO2017223491A1 (en) 2016-06-23 2017-12-28 Health Research, Inc. Pharmaceutical compositions with antiflaviviral activity
BR112019000796A2 (pt) 2016-07-16 2019-04-24 Florida State University Research Foundation, Inc. compostos e métodos para tratamento e prevenção da infecção flavivirus
KR101928543B1 (ko) 2017-01-09 2018-12-13 사단법인 분자설계연구소 니클로사마이드를 함유하는 Axin-GSK3 단백질 결합 관련 질환 치료용 약학조성물
US20210052621A1 (en) 2017-01-17 2021-02-25 The Regents Of The University Of California Methods for treating flaviviruses and zika infections
CN110381960A (zh) 2017-02-02 2019-10-25 麦克马斯特大学 作为抗微生物剂的增强剂的碳酸氢盐
JP7298928B2 (ja) 2017-03-21 2023-06-27 ノヴァリード ファーマ インク ホスホジエステラーゼの阻害及びその関連障害のための治療剤
FI3612262T3 (fi) 2017-04-18 2024-01-16 Inspiring Pty Ltd Kuivajauheinhalaattori ja kuivajauheinhalaattorin tilanjatkeväline
US11807906B2 (en) 2017-05-08 2023-11-07 The Governors Of The University Of Alberta Peroxisome biomarkers in HIV disease progression and peroxisome activating drugs for HIV treatment
CA3064005C (en) 2017-05-19 2023-03-07 Pneuma Respiratory, Inc. Dry powder delivery device and methods of use
WO2019051437A1 (en) 2017-09-11 2019-03-14 Board Of Regents, The University Of Texas System COMPOSITIONS FOR ENHANCED MEDICATION DELIVERY
US20200405643A1 (en) 2017-09-11 2020-12-31 Board Of Regents, The University Of Texas System Drug compositions containing porous carriers made by thermal or fusion-based processes
CA3085943A1 (en) 2017-12-21 2019-06-27 Civitas Therapeutics, Inc. Surfactant formulations for inhalation
US20210161937A1 (en) 2018-01-23 2021-06-03 The Trustees Of Columbia University In The City Of New York Activation of mitochondrial uncoupling as a therapeutic intervention
WO2019217164A1 (en) 2018-05-09 2019-11-14 Reyoung Corporation Compositions and methods for treating cancer and other diseases
US11166926B2 (en) 2018-08-08 2021-11-09 The Hospital For Sick Children Compositions and methods for protecting a host from enteric toxigenic pathogens
PH12022550448A1 (en) 2019-08-23 2022-12-12 Daewoong Pharmaceutical Co Ltd Niclosamide delayed-release composition and antiviral use thereof
US20210114973A1 (en) 2019-10-18 2021-04-22 First Wave Bio, Inc. Pharmaceutical formulations
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
US11045434B1 (en) 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease

Similar Documents

Publication Publication Date Title
JP2018529762A5 (enExample)
JP7136886B2 (ja) Hivカプシド阻害剤の固体形態
JP7083398B2 (ja) ピリジン誘導体およびhiv感染を処置するためのその使用
JP6632746B2 (ja) 癌を治療するための1−テトラヒドロピラニルカルボニル−2,3−ジヒドロ−1h−インドール化合物
BR122020006907B1 (pt) Anticorpo de domínio único anti-kras e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipetídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
JP2021522195A (ja) N−((1,2,3,5,6,7−ヘキサヒドロ−s−インダセン−4−イル)カルバモイル)−1−イソプロピル−1H−ピラゾール−3−スルホンアミドのナトリウム塩
JP2021532154A (ja) 抗hiv化合物
TW202342449A (zh) 治療性化合物
JP2022511029A (ja) がんの処置のための薬剤としての使用のためのcdk9インヒビターおよびその多形
US11911348B2 (en) Therapeutic agent for cancer
EP3680232B1 (en) Novel anthranilic acid-based compound, and pin1 inhibitor, therapeutic agent for inflammatory diseases and therapeutic agent for cancer that use the same
CN111936502B (zh) 杂二环羧酸及其盐
JP2013528656A5 (enExample)
JP2016501838A (ja) 併用療法
US20220402884A1 (en) (s)-n-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-carboxamide and pharmaceutically acceptable salts thereof
CN117643587A (zh) 用于治疗癌症的杂二环羧酸
JP7229482B2 (ja) 新規アミド系化合物、並びにそれを用いたPin1阻害剤、炎症性疾患の治療剤及び癌の治療剤
KR20150073997A (ko) 암을 치료하기 위해 이용될 수 있는 인게놀-유도 화합물
CN107708696B (zh) 炎症性肠病的预防或治疗用药剂
TW202523303A (zh) 用於治療發炎性腸道疾病之化合物及方法
JP2018516947A5 (enExample)
JP2025527765A (ja) Ep4受容体アンタゴニストとしての複素二環式化合物
CN119301100A (zh) 新型1,2-二氨基苯并咪唑衍生物
HK40062414A (en) (s)-n-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-carboxamide and pharmaceutically acceptable salts thereof
WO2018012634A1 (ja) 不飽和複素5員環含有化合物を含有する肺高血圧症の予防又は治療剤